



JUXTAPID (Iomitapide)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

<u>Part A – Patient</u> Patient Information

ratient informatio)II			
First Name:			Last Name:	
Insurance Carrier N	lame/Number:			
Group Number:			Client ID:	
Date of Birth (YYYY,	/MM/DD):		Relationship: Em	nployee Spouse Dependent
Language: Eng	lish French		Gender: Male	Female
Address:			<u> </u>	
City:		Province:		Postal Code:
Email address:				
Telephone (home):		Telephone (cell):		Telephone (work):
The patient is a from the educat The patient is a	tional institution confirm	endent (i.e. attending ling full-time status is eover age 18. The patie	enclosed. ent has signed the auth	ull-time). A copy of the enrolment document norization section below that allows Sun Life
Coordination of be	enefits			
Provincial Coverage		•		To find out if you qualify for coverage, response letter to your pharmacist when
Primary Coverage	Has the patient applied What is the coverage d	_		Yes No N/A ed *Attach decision letter*





JUXTAPID (lomitapide)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Debiant Cignature (if aver 40 years of age)	Data
Patient Signature (if over 18 years of age)	Date





JUXTAPID (lomitapide)

Part B - Prescriber

SECTION 1 - DRUG REQUESTED

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

5 1817.)						
DIN(s)	Dose	Administration	on (ex: oral, IV,	etc)	Frequency	Duratio
 Bite of drug administration	on:					
Home Physic	cian's office/Private Clin	ic Pri	ivate Clinic (wit	thin Hospita	l - no public or g	overnment fundin
Hospital (inpatient)	Hospital (outpat	ient)				
Name of the hospital or i						
	-					
Address:						
	1			I		
City:	Prov	vince:			Postal code:	
* Please submit proof	of prior coverage if avail	able				
	p 33.31483 ii dvaii					
SECTION 2 - ELIGIBI	LITY CRITERIA					
1. Please indicate if th	ne patient satisfies the b	elow criteria:				
Familial Hypercholester	olemia					
	olema					
INITIAL	.8 years or older, AND					
INITIAL The patient is 1 Treatment is pro-	.8 years or older, AND escribed and supervised nolesterolemia, AND	d by a specialis	st physician ex	perienced ir	n the diagnosis a	and treatment of
INITIAL The patient is 1 Treatment is prefamilial hyperch	escribed and supervised nolesterolemia, AND s a confirmed diagnosis			-	_	
INITIAL The patient is 1 Treatment is prefamilial hyperch The patient has indication, AND	escribed and supervised nolesterolemia, AND s a confirmed diagnosis	of familial hyp	ercholesterole	mia, as per	_	
INITIAL The patient is 1 Treatment is prefamilial hyperch The patient has indication, AND The patient has	escribed and supervised nolesterolemia, AND s a confirmed diagnosis	of familial hypomol/L or non-l	ercholesterole HDL-C≥2.6mr	mia, as per mol/L, AND	_	
INITIAL The patient is 1 Treatment is prefamilial hyperch The patient has indication, AND The patient has	escribed and supervised nolesterolemia, AND s a confirmed diagnosis of a fasting LDL-C ≥ 1.8m three most recent chole	of familial hypomol/L or non-l	ercholesterole HDL-C≥2.6mr	mia, as per mol/L, AND	the Health Cana	
INITIAL The patient is 1 Treatment is prefamilial hyperch The patient has indication, AND The patient has	escribed and supervised nolesterolemia, AND s a confirmed diagnosis of a fasting LDL-C ≥ 1.8m three most recent chole	of familial hyp mol/L or non-l sterol or lipid	ercholesterole HDL-C \geq 2.6mr panel results, ρ	mia, as per mol/L, AND AND	the Health Cana	ada approved
INITIAL The patient is 1 Treatment is prefamilial hyperch The patient has indication, AND The patient has Please provide	escribed and supervised nolesterolemia, AND s a confirmed diagnosis of a fasting LDL-C ≥ 1.8m three most recent chole	of familial hyp mol/L or non-l sterol or lipid	ercholesterole HDL-C \geq 2.6mr panel results, ρ	mia, as per mol/L, AND AND	the Health Cana	ada approved





JUXTAPID (lomitapide)

JUXTAPID will be use AND	ed in combination w	vith other stan	dard lipid-low	ering therapies.	Please spec	ify drugs and dose
Please describe sign		neart disease	or attach the	most recent car	diologist clini	ical consult report
not include genetic	test results):					
/AL Please provide the o	date the patient star	rted treatmen	t with JUXTAP	ID:		AND
Please provide three	e most recent chole	sterol or lipid	panel results,	AND		
	Total Cholesterol	HDL-C	LDL-C	Triglycerides	VLDL-C	Non-HDL-C
Date (YYYY-MM-DD)						
Date (YYYY-MM-DD)						
Date (YYYY-MM-DD)						
Date (YYYY-MM-DD)						
JUXTAPID will be use AND	ed in combination w	vith other stan	dard lipid-low	ering therapies.	Please spec	ify drugs and dose
JUXTAPID will be use	ed in combination w	vith other stan	dard lipid-low	ering therapies.	Please spec	ify drugs and dose
JUXTAPID will be use	ns or symptoms of h					





JUXTAPID (Iomitapide)

OR	
☐ The patient does not meet the above criteria. Please pro	ovide rationale for prescribing treatment (do not provide
genetic test results):	
SECTION 3 - PRESCRIBER INFORMATION	
SECTION 5 - FRESCRIBER INFORMATION	
Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature	Date:

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





JUXTAPID (lomitapide)

SECTION 5 - CONTACT US

reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept.
PO Box 2010 STN Waterloo
Waterloo, ON N2J 0A6